Will Pfizer’s pill shake up the obesity market?

Pfizer is developing a once-daily oral weight loss pill called danuglipron to compete in the booming obesity drug market. The drug will compete against products from Novo Nordisk and Eli Lilly. Oral weight loss pills are increasingly popular due to their convenience and are generally cheaper than injections. Before reaching the market, Pfizer’s danuglipron must successfully undergo large-scale clinical trials to prove its safety and efficacy.